Medpace (NASDAQ:MEDP) Releases FY 2026 Earnings Guidance

Key Points

• Medpace raised its FY 2026 outlook, forecasting EPS of $17.97–$18.32 versus the $17.68 analyst consensus. Revenue is expected to reach $2.8–$2.9 billion, broadly in line with estimates.
• The company’s latest quarter exceeded expectations, with EPS of $4.84 versus $4.44 expected and revenue of $716 million, up 8.5% year over year.
• Despite stronger guidance and results, analysts maintain a consensus “Hold” rating with a $638.27 price target, while the CEO and other insiders have sold significant shares recently.

Medpace (NASDAQ:MEDP - Get Free Report) updated its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 17.970-18.320 for the period, compared to the consensus earnings per share estimate of 17.680. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Medpace Price Performance

Shares of MEDP stock traded up $4.65 during mid-day trading on Friday, hitting $658.61. 53,088 shares of the stock traded hands, compared to its average volume of 331,522. The stock has a market cap of $18.38 billion, a P/E ratio of 38.57, a P/E/G ratio of 2.96 and a beta of 1.18. The stock's fifty day moving average is $609.84 and its two-hundred day moving average is $536.74. Medpace has a 52-week low of $373.00 and a 52-week high of $684.52.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Wednesday, October 21st. The company reported $4.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.44 by $0.40. The firm had revenue of $716.00 million for the quarter, compared to the consensus estimate of $714.47 million. Medpace had a net margin of 18.24% and a return on equity of 104.17%. The company's quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.86 EPS. As a group, equities analysts forecast that Medpace will post 17.54 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on MEDP. Robert W. Baird set a $699.00 price objective on Medpace in a report on Friday. BMO Capital Markets boosted their target price on Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a research note on Friday, July 24th. Royal Bank Of Canada upped their target price on Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a research report on Friday, July 24th. Barclays upped their target price on Medpace from $625.00 to $675.00 and gave the company an "equal weight" rating in a research report on Friday. Finally, Weiss Ratings upgraded Medpace from a "buy (b-)" rating to a "buy (b)" rating in a research note on Thursday, October 8th. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $638.27.

Insiders Place Their Bets

In other Medpace news, CEO August Troendle sold 21,966 shares of the company's stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $625.47, for a total transaction of $13,739,074.02. Following the transaction, the chief executive officer owned 338,225 shares in the company, valued at approximately $211,549,590.75. This represents a 6.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 336,140 shares of company stock worth $208,008,328. 20.50% of the stock is currently owned by insiders.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Raised 2026 outlook: Medpace now expects full-year EPS of $17.97–$18.32, above the $17.68 analyst consensus. Revenue guidance of $2.8–$2.9 billion is also at or above expectations. Medpace forecasts 2026 EPS and buyback
• Positive Sentiment: Quarterly results exceeded expectations: Third-quarter EPS was $4.84 versus the $4.44 consensus, while revenue rose 8.5% year over year to $716 million, slightly ahead of forecasts. Net margin was 18.24%. Medpace third-quarter 2026 results
• Positive Sentiment: Demand indicators remained healthy: Third-quarter net new business awards reached $873 million, and ending backlog grew 5.6% year over year to $3.2 billion, supporting future revenue visibility. Medpace three key takeaways
• Positive Sentiment: $1 billion buyback: The new authorization replaces the prior program and signals management confidence while potentially supporting per-share results. Medpace buyback and third-quarter profit
• Neutral Sentiment: Deutsche Bank raised its price target to $650 from $535 but retained a Hold rating, indicating improved fundamentals may already be reflected in the share price. Deutsche Bank Medpace price target
• Negative Sentiment: Investors remain concerned that Medpace is expensive, with commentary suggesting the stock may be about 24% overvalued. Those concerns help explain why the shares decreased even after the earnings beat and raised outlook. Medpace valuation analysis

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace's services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.